Candel therapeutics announces new data from ongoing phase 1 clinical trial of can-3110 in recurrent high-grade glioma at the american society of gene & cell therapy (asgct) 26th annual meeting

Needham, mass., may 19, 2023 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced new data from an ongoing phase 1 investigator-sponsored clinical trial of its herpes simplex virus-1 (hsv-1) replication-competent viral immunotherapy candidate, can-3110, in patients with high-grade glioma that has recurred after standard of care (soc) treatment. the data were presented today in an oral presentation session at the 26th annual meeting of the american society of gene & cell therapy (asgct).
CADL Ratings Summary
CADL Quant Ranking